Wenlei Jiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11111717/publications.pdf

Version: 2024-02-01

47 papers	1,780 citations	331670 21 h-index	302126 39 g-index
48 all docs	48 docs citations	48 times ranked	2230 citing authors

#	Article	IF	Citations
1	Analysis of verteporfin liposomal formulations for phospholipids and phospholipid degradation products by liquid chromatography-mass spectrometry (LC-MS). Journal of Pharmaceutical and Biomedical Analysis, 2022, 208, 114473.	2.8	8
2	Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy. Epilepsy and Behavior, 2022, 128, 108587.	1.7	0
3	Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms. AAPS Journal, 2022, 24, 40.	4.4	11
4	Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. Molecular Pharmaceutics, 2021, 18, 1544-1557.	4.6	5
5	Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy. Pharmaceutical Research, 2020, 37, 60.	3.5	1
6	Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Epilepsy and Behavior, 2020, 105, 106936.	1.7	3
7	Quantification of phospholipid degradation products in liposomal pharmaceutical formulations by ultra performance liquid chromatography-mass spectrometry (UPLC-MS). International Journal of Pharmaceutics, 2020, 578, 119077.	5.2	18
8	Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation. International Journal of Pharmaceutics, 2019, 569, 118603.	5.2	15
9	Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatographyâ€“Inductively Coupled Plasmaâ€“Mass Spectrometric Approach. Molecular Pharmaceutics, 2019, 16, 1272-1281.	4.6	14
10	Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: â€œDrug Products, Including Biological Products, that Contain Nanomaterialsâ€• AAPS Journal, 2019, 21, 56.	4.4	28
11	Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 107-116.	4.3	30
12	A Survey of Patientsâ€™ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. Journal of General Internal Medicine, 2019, 34, 420-428.	2.6	8
13	Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy. Epilepsy and Behavior, 2019, 90, 197-203.	1.7	7
14	Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. American Journal of Transplantation, 2019, 19, 1410-1420.	4.7	79
15	Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets*. Journal of Pharmaceutical Sciences, 2019, 108, 1189-1194.	3.3	12
16	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clinical Pharmacology and Therapeutics, 2018, 103, 1093-1099.	4.7	13
17	Evaluation of Switching Patterns in FDAâ€™s Sentinel System: A New Tool to Assess Generic Drugs. Drug Safety, 2018, 41, 1313-1323.	3.2	12
18	Direct quantification of unencapsulated doxorubicin in liposomal doxorubicin formulations using capillary electrophoresis. International Journal of Pharmaceutics, 2018, 549, 109-114.	5.2	22

#	Article	IF	Citations
19	Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization. Nanomaterials, 2018, 8, 25.	4.1	15
20	In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations. Regulatory Toxicology and Pharmacology, 2018, 97, 17-23.	2.7	6
21	Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials. AAPS Journal, 2017, 19, 619-631.	4.4	39
22	Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. Drugs, 2017, 77, 427-433.	10.9	7
23	InÂVitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules. Journal of Pharmaceutical Sciences, 2017, 106, 1859-1864.	3.3	11
24	How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. AAPS Journal, 2017, 19, 1071-1083.	4.4	22
25	Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs. Current Neurology and Neuroscience Reports, 2017, 17, 82.	4.2	4
26	In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration. AAPS Journal, 2017, 19, 1593-1599.	4.4	3
27	Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy. JAMA Neurology, 2017, 74, 919.	9.0	41
28	Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. AAPS Journal, 2017, 19, 150-160.	4.4	30
29	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Medicine, 2017, 14, e1002428.	8.4	29
30	Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. Pharmacoepidemiology and Drug Safety, 2016, 25, 944-952.	1.9	5
31	Reply to â€œOn the Effect of Common Excipients on the Oral Absorption of Class 3 Drugsâ€• Journal of Pharmaceutical Sciences, 2016, 105, 1355-1357.	3.3	5
32	Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences, 2016, 105, 996-1005.	3.3	43
33	Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine. Therapeutic Drug Monitoring, 2016, 38, 728-737.	2.0	8
34	Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurology, The, 2016, 15, 365-372.	10.2	79
35	Generic lamotrigine versus brandâ€name <scp>Lamictal</scp> bioequivalence in patients with epilepsy: A field test of the <scp>FDA</scp> bioequivalence standard. Epilepsia, 2015, 56, 1415-1424.	5.1	68
36	Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Molecular Pharmaceutics, 2015, 12, 2436-2443.	4.6	25

#	Article	IF	Citations
37	Quantification of Lamotrigine in Patient Plasma Using a Fast Liquid Chromatographyâ€“Tandem Mass Spectrometry Method With Backflush Technology. Therapeutic Drug Monitoring, 2015, 37, 188-197.	2.0	8
38	A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion. AAPS Journal, 2015, 17, 891-901.	4.4	45
39	Bioequivalence for Liposomal Drug Products. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 275-296.	0.6	7
40	CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products. AAPS Journal, 2013, 15, 623-628.	4.4	18
41	In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis, 2011, 3, 333-344.	1.5	96
42	The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. International Journal of Pharmaceutics, 2011, 418, 151-160.	5.2	81
43	Stabilization of Tetanus Toxoid Encapsulated in PLGA Microspheres. Molecular Pharmaceutics, 2008, 5, 808-817.	4.6	58
44	Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Advanced Drug Delivery Reviews, 2005, 57, 391-410.	13.7	429
45	Stabilization of a Model Formalinized Protein Antigen Encapsulated in Poly(lactideâ€coâ€glycolide)â€Based Microspheres. Journal of Pharmaceutical Sciences, 2001, 90, 1558-1569.	3.3	42
46	Stabilization and controlled release of bovine serum albumin encapsulated in poly(D, L-lactide) and poly(ethylene glycol) microsphere blends. , 2001, 18, 878-885.		175
47	Formaldehyde-mediated aggregation of protein antigens: Comparison of untreated and formalinized model antigens. Biotechnology and Bioengineering, 2000, 70, 507-517.	3.3	38